Date: 2014-02-20
Type of information: Clinical research agreement
Compound:
Company: PPD (USA) Charité–Universitätsmedizin Berlin (Germany)
Therapeutic area:
Type agreement: collaboration
clinical research
Action mechanism:
Disease:
Details: * On February 20, 2014, Pharmaceutical Product Development (PPD) and the Charité–Universitätsmedizin Berlin have announced a new collaboration between the company and the hospital’s clinical trials management unit (CTMU) to increase the volume of clinical trials conducted in Germany, improve access to commercial clinical research for patients, accelerate the development of new medicines and enhance health care treatment opportunities for German citizens. The collaboration builds upon the long-standing relationship between PPD and the Charité, one of the largest and most well-respected university hospitals in Europe. With 13,200 employees, the hospital maintains more than 100 clinics and institutes within 17 CharitéCenters at its four campuses.
PPD will collaborate with the CTMU to shorten study start-up times, maximize the number of patients recruited for clinical trials, generate continued high-quality data and ensure all site staff members are trained as necessary for the conduct of clinical studies.
The agreement includes a wide range of Phase I-IV trials across multiple therapeutic areas. Key focus areas for the CTMU include hematology/oncology, cardiovascular, neurology, psychiatry, respiratory, rheumatology, anesthesia, dermatology, nephrology, urology and women\'s health.
Financial terms:
Latest news:
